vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and DELUXE CORP (DLX). Click either name above to swap in a different company.

DELUXE CORP is the larger business by last-quarter revenue ($535.2M vs $487.7M, roughly 1.1× CLOVER HEALTH INVESTMENTS, CORP.). DELUXE CORP runs the higher net margin — 2.2% vs -10.1%, a 12.3% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 2.8%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 0.0%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Deluxe Corporation is an American company that provides payment processing, data services, checks and promotional products, and merchant services. It operates in four divisions: B2B payments, data, print, and merchant services. As of 2025, the company serves millions of small businesses and thousands of financial institutions, processing more than $2.8 trillion in payments annually. While its legacy business centers on check printing and other printed products, payments and data services now ...

CLOV vs DLX — Head-to-Head

Bigger by revenue
DLX
DLX
1.1× larger
DLX
$535.2M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+41.9% gap
CLOV
44.7%
2.8%
DLX
Higher net margin
DLX
DLX
12.3% more per $
DLX
2.2%
-10.1%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
0.0%
DLX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
DLX
DLX
Revenue
$487.7M
$535.2M
Net Profit
$-49.3M
$12.0M
Gross Margin
52.2%
Operating Margin
-10.1%
8.9%
Net Margin
-10.1%
2.2%
Revenue YoY
44.7%
2.8%
Net Profit YoY
-123.2%
-5.0%
EPS (diluted)
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
DLX
DLX
Q4 25
$487.7M
$535.2M
Q3 25
$496.6M
$540.2M
Q2 25
$477.6M
$521.3M
Q1 25
$462.3M
$536.5M
Q4 24
$337.0M
$520.6M
Q3 24
$331.0M
$528.4M
Q2 24
$356.3M
$537.8M
Q1 24
$346.9M
$535.0M
Net Profit
CLOV
CLOV
DLX
DLX
Q4 25
$-49.3M
$12.0M
Q3 25
$-24.4M
$33.7M
Q2 25
$-10.6M
$22.4M
Q1 25
$-1.3M
$14.0M
Q4 24
$-22.1M
$12.6M
Q3 24
$-9.2M
$8.9M
Q2 24
$7.4M
$20.5M
Q1 24
$-19.2M
$10.8M
Gross Margin
CLOV
CLOV
DLX
DLX
Q4 25
52.2%
Q3 25
53.9%
Q2 25
53.6%
Q1 25
52.4%
Q4 24
52.3%
Q3 24
24.5%
53.3%
Q2 24
30.3%
53.7%
Q1 24
23.6%
53.0%
Operating Margin
CLOV
CLOV
DLX
DLX
Q4 25
-10.1%
8.9%
Q3 25
-4.9%
14.0%
Q2 25
-2.2%
11.7%
Q1 25
-0.3%
9.0%
Q4 24
-6.4%
9.0%
Q3 24
-2.7%
7.9%
Q2 24
2.0%
11.0%
Q1 24
-6.5%
8.3%
Net Margin
CLOV
CLOV
DLX
DLX
Q4 25
-10.1%
2.2%
Q3 25
-4.9%
6.2%
Q2 25
-2.2%
4.3%
Q1 25
-0.3%
2.6%
Q4 24
-6.6%
2.4%
Q3 24
-2.8%
1.7%
Q2 24
2.1%
3.8%
Q1 24
-5.5%
2.0%
EPS (diluted)
CLOV
CLOV
DLX
DLX
Q4 25
$0.25
Q3 25
$0.74
Q2 25
$0.50
Q1 25
$0.31
Q4 24
$0.28
Q3 24
$0.20
Q2 24
$0.46
Q1 24
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
DLX
DLX
Cash + ST InvestmentsLiquidity on hand
$78.3M
$36.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$680.7M
Total Assets
$541.0M
$2.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
DLX
DLX
Q4 25
$78.3M
$36.9M
Q3 25
$25.8M
Q2 25
$26.0M
Q1 25
$30.3M
Q4 24
$194.5M
$34.4M
Q3 24
$288.0M
$41.3M
Q2 24
$254.8M
$23.1M
Q1 24
$208.3M
$23.5M
Stockholders' Equity
CLOV
CLOV
DLX
DLX
Q4 25
$308.7M
$680.7M
Q3 25
$340.9M
$664.1M
Q2 25
$344.2M
$638.7M
Q1 25
$336.1M
$622.5M
Q4 24
$341.1M
$620.9M
Q3 24
$342.2M
$612.7M
Q2 24
$324.9M
$620.5M
Q1 24
$292.5M
$608.4M
Total Assets
CLOV
CLOV
DLX
DLX
Q4 25
$541.0M
$2.9B
Q3 25
$559.7M
$2.6B
Q2 25
$575.0M
$2.5B
Q1 25
$583.7M
$2.6B
Q4 24
$580.7M
$2.8B
Q3 24
$653.0M
$2.6B
Q2 24
$674.2M
$2.7B
Q1 24
$671.8M
$2.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
DLX
DLX
Operating Cash FlowLast quarter
$-66.9M
$102.1M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
8.53×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
DLX
DLX
Q4 25
$-66.9M
$102.1M
Q3 25
$12.1M
$67.1M
Q2 25
$5.4M
$51.1M
Q1 25
$-16.3M
$50.3M
Q4 24
$34.8M
$60.2M
Q3 24
$50.0M
$67.9M
Q2 24
$44.8M
$39.6M
Q1 24
$25.9M
$26.6M
Free Cash Flow
CLOV
CLOV
DLX
DLX
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
$27.8M
Q1 25
$-16.5M
$24.3M
Q4 24
$33.3M
Q3 24
$49.6M
$46.7M
Q2 24
$44.4M
$11.4M
Q1 24
$25.5M
$6.1M
FCF Margin
CLOV
CLOV
DLX
DLX
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
5.3%
Q1 25
-3.6%
4.5%
Q4 24
9.9%
Q3 24
15.0%
8.8%
Q2 24
12.5%
2.1%
Q1 24
7.3%
1.1%
Capex Intensity
CLOV
CLOV
DLX
DLX
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
4.5%
Q1 25
0.0%
4.8%
Q4 24
0.5%
Q3 24
0.1%
4.0%
Q2 24
0.1%
5.2%
Q1 24
0.1%
3.8%
Cash Conversion
CLOV
CLOV
DLX
DLX
Q4 25
8.53×
Q3 25
1.99×
Q2 25
2.28×
Q1 25
3.59×
Q4 24
4.77×
Q3 24
7.60×
Q2 24
6.04×
1.94×
Q1 24
2.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

DLX
DLX

Services$247.9M46%
B2B Payments$76.3M14%
Datadrivenmarketingsolutions$68.5M13%
Promotional Solutions Revenue$60.9M11%
Treasurymanagementsolutions$59.8M11%
Other$17.3M3%
Other Web Based Solutions$4.6M1%

Related Comparisons